ERBB2 and breast carcinoma: T-DM1 is also a recommended option for adjuvant therapy in patients with HER2-positive breast cancer according to the guidelines (24,25), based on the KATHERINE phase III study demonstrating that T-DM1 is a superior choice of adjuvant therapy for invasive HER2-positive breast cancer compared with trastuzumab (26).